Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

Francesca R. Mauro; Stefano Molica; Luca Laurenti; Agostino Cortelezzi; Angelo M. Carella; Francesco Zaja; Annalisa Chiarenza; Francesco Angrilli; Francesco Nobile; Roberto Marasca; Caterina Musolino; Maura Brugiatelli; Alfonso Piciocchi; Marco Vignetti; Paola Fazi; Giuseppe Gentile; Maria S. De Propris; Irene Della Starza; Marilisa Marinelli; Sabina Chiaretti; Ilaria Del Giudice; Mauro Nanni; Francesco Albano; Antonio Cuneo; Anna Guarini; Robin Foà

doi:10.1016/j.leukres.2013.11.009

Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

Francesca R. Mauro, Stefano Molica, Luca Laurenti, Agostino Cortelezzi, Angelo M. Carella, Francesco Zaja, Annalisa Chiarenza, Francesco Angrilli, Francesco Nobile, Roberto Marasca, Caterina Musolino, Maura Brugiatelli, Alfonso Piciocchi, Marco Vignetti, Paola Fazi, Giuseppe Gentile, Maria S. De Propris, Irene Della Starza, Marilisa Marinelli, Sabina ChiarettiIlaria Del Giudice, Mauro Nanni, Francesco Albano, Antonio Cuneo, Anna Guarini, Robin Foà

Research output: Contribution to journal › Article › peer-review

Abstract

In 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab^®) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.

Original language	English
Pages (from-to)	198-203
Number of pages	6
Journal	Leukemia Research
Volume	38
Issue number	2
DOIs	https://doi.org/10.1016/j.leukres.2013.11.009
Publication status	Published - Feb 2014

Keywords

Alemtuzumab
Biology
Chronic lymphocytic leukemia
CLL
Fludarabine
Young

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology
Medicine(all)

Access to Document

10.1016/j.leukres.2013.11.009

Fingerprint Dive into the research topics of 'Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile'. Together they form a unique fingerprint.

Cite this

Mauro, F. R., Molica, S., Laurenti, L., Cortelezzi, A., Carella, A. M., Zaja, F., Chiarenza, A., Angrilli, F., Nobile, F., Marasca, R., Musolino, C., Brugiatelli, M., Piciocchi, A., Vignetti, M., Fazi, P., Gentile, G., De Propris, M. S., Starza, I. D., Marinelli, M., ... Foà, R. (2014). Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. Leukemia Research, 38(2), 198-203. https://doi.org/10.1016/j.leukres.2013.11.009

Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. / Mauro, Francesca R.; Molica, Stefano; Laurenti, Luca; Cortelezzi, Agostino; Carella, Angelo M.; Zaja, Francesco; Chiarenza, Annalisa; Angrilli, Francesco; Nobile, Francesco; Marasca, Roberto; Musolino, Caterina; Brugiatelli, Maura; Piciocchi, Alfonso; Vignetti, Marco; Fazi, Paola; Gentile, Giuseppe; De Propris, Maria S.; Starza, Irene Della; Marinelli, Marilisa; Chiaretti, Sabina; Del Giudice, Ilaria; Nanni, Mauro; Albano, Francesco; Cuneo, Antonio; Guarini, Anna; Foà, Robin.

In: Leukemia Research, Vol. 38, No. 2, 02.2014, p. 198-203.

Research output: Contribution to journal › Article › peer-review

Mauro, FR, Molica, S, Laurenti, L, Cortelezzi, A, Carella, AM, Zaja, F, Chiarenza, A, Angrilli, F, Nobile, F, Marasca, R, Musolino, C, Brugiatelli, M, Piciocchi, A, Vignetti, M, Fazi, P, Gentile, G, De Propris, MS, Starza, ID, Marinelli, M, Chiaretti, S, Del Giudice, I, Nanni, M, Albano, F, Cuneo, A, Guarini, A & Foà, R 2014, 'Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile', Leukemia Research, vol. 38, no. 2, pp. 198-203. https://doi.org/10.1016/j.leukres.2013.11.009

Mauro, Francesca R. ; Molica, Stefano ; Laurenti, Luca ; Cortelezzi, Agostino ; Carella, Angelo M. ; Zaja, Francesco ; Chiarenza, Annalisa ; Angrilli, Francesco ; Nobile, Francesco ; Marasca, Roberto ; Musolino, Caterina ; Brugiatelli, Maura ; Piciocchi, Alfonso ; Vignetti, Marco ; Fazi, Paola ; Gentile, Giuseppe ; De Propris, Maria S. ; Starza, Irene Della ; Marinelli, Marilisa ; Chiaretti, Sabina ; Del Giudice, Ilaria ; Nanni, Mauro ; Albano, Francesco ; Cuneo, Antonio ; Guarini, Anna ; Foà, Robin. / Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. In: Leukemia Research. 2014 ; Vol. 38, No. 2. pp. 198-203.

@article{f5d70c0fd4084d4a806b3666809eff26,

title = "Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile",

abstract = "In 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab{\textregistered}) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.",

keywords = "Alemtuzumab, Biology, Chronic lymphocytic leukemia, CLL, Fludarabine, Young",

author = "Mauro, {Francesca R.} and Stefano Molica and Luca Laurenti and Agostino Cortelezzi and Carella, {Angelo M.} and Francesco Zaja and Annalisa Chiarenza and Francesco Angrilli and Francesco Nobile and Roberto Marasca and Caterina Musolino and Maura Brugiatelli and Alfonso Piciocchi and Marco Vignetti and Paola Fazi and Giuseppe Gentile and {De Propris}, {Maria S.} and Starza, {Irene Della} and Marilisa Marinelli and Sabina Chiaretti and {Del Giudice}, Ilaria and Mauro Nanni and Francesco Albano and Antonio Cuneo and Anna Guarini and Robin Fo{\`a}",

year = "2014",

month = feb,

doi = "10.1016/j.leukres.2013.11.009",

language = "English",

volume = "38",

pages = "198--203",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "2",

}

TY - JOUR

T1 - Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

AU - Mauro, Francesca R.

AU - Molica, Stefano

AU - Laurenti, Luca

AU - Cortelezzi, Agostino

AU - Carella, Angelo M.

AU - Zaja, Francesco

AU - Chiarenza, Annalisa

AU - Angrilli, Francesco

AU - Nobile, Francesco

AU - Marasca, Roberto

AU - Musolino, Caterina

AU - Brugiatelli, Maura

AU - Piciocchi, Alfonso

AU - Vignetti, Marco

AU - Fazi, Paola

AU - Gentile, Giuseppe

AU - De Propris, Maria S.

AU - Starza, Irene Della

AU - Marinelli, Marilisa

AU - Chiaretti, Sabina

AU - Del Giudice, Ilaria

AU - Nanni, Mauro

AU - Albano, Francesco

AU - Cuneo, Antonio

AU - Guarini, Anna

AU - Foà, Robin

PY - 2014/2

Y1 - 2014/2

N2 - In 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab®) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.

AB - In 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab®) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.

KW - Alemtuzumab

KW - Biology

KW - Chronic lymphocytic leukemia

KW - CLL

KW - Fludarabine

KW - Young

UR - http://www.scopus.com/inward/record.url?scp=84892510314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892510314&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2013.11.009

DO - 10.1016/j.leukres.2013.11.009

M3 - Article

C2 - 24314589

AN - SCOPUS:84892510314

VL - 38

SP - 198

EP - 203

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 2

ER -

Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this